CU24361B1 - (aza)piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinólisis - Google Patents

(aza)piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinólisis

Info

Publication number
CU24361B1
CU24361B1 CU2016000062A CU20160062A CU24361B1 CU 24361 B1 CU24361 B1 CU 24361B1 CU 2016000062 A CU2016000062 A CU 2016000062A CU 20160062 A CU20160062 A CU 20160062A CU 24361 B1 CU24361 B1 CU 24361B1
Authority
CU
Cuba
Prior art keywords
aza
bleeding
prophylaxis
treatment
pyridopirazolopirimidinones
Prior art date
Application number
CU2016000062A
Other languages
English (en)
Inventor
Kristin Beyer
Dr Nils Burkhard
Grande Dr Yolanda Cancho
Dr Manuel Ellermann
Dr Jorma Hassfeld
Dr Tom Kinzel
Dr Johannes Köbberling
Dr Maria Köllnberger
Susanne Röhrig
Dr Karl-Heinz Schlemmer
Dr Joachim Schumacher
Dr Michael Sperzel
Dr Christian Stegmann
Dr Matthias Werner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU24361B1 publication Critical patent/CU24361B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se relaciona con nuevas (aza)piridopirazolopirimidinonas e indazolopirimidinonas sustituidas de fórmulas I-A y I-B</p> <p>ESPACIO PARA FÓRMULA</p> <p>y con procesos para su preparación. Estos compuestos son útiles para el tratamiento y/o profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de sangrado agudo y recurrente en pacientes con o sin trastornos de sangrado hereditarios o adquiridos subyacentes, en donde el sangrado está asociado con una enfermedad o intervención médica que se elige del grupo que consiste en menorragia, hemorragia posparto, choque hemorrágico, trauma, cirugía, trasplante, infarto, enfermedades hepáticas, angioedema hereditario, sangrado de nariz, y sinovitis y daño de cartílago luego de hemartrosis.</p>
CU2016000062A 2013-11-05 2014-11-03 (aza)piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinólisis CU24361B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13191642 2013-11-05
PCT/EP2014/073529 WO2015067549A1 (en) 2013-11-05 2014-11-03 (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis

Publications (1)

Publication Number Publication Date
CU24361B1 true CU24361B1 (es) 2018-10-04

Family

ID=49517406

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000062A CU24361B1 (es) 2013-11-05 2014-11-03 (aza)piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinólisis

Country Status (29)

Country Link
US (3) US9598417B2 (es)
EP (1) EP3066100B1 (es)
JP (1) JP6431061B2 (es)
KR (1) KR102312780B1 (es)
CN (1) CN105683194B (es)
AP (1) AP2016009175A0 (es)
AR (1) AR098292A1 (es)
AU (1) AU2014345771B2 (es)
CA (1) CA2929378C (es)
CL (1) CL2016001076A1 (es)
CR (1) CR20160332A (es)
CU (1) CU24361B1 (es)
DO (1) DOP2016000102A (es)
EA (1) EA029373B1 (es)
ES (1) ES2732305T3 (es)
GT (1) GT201600084A (es)
HK (1) HK1223940A1 (es)
IL (1) IL244645B (es)
MA (1) MA39018A1 (es)
MX (1) MX370419B (es)
PE (1) PE20160934A1 (es)
PH (1) PH12016500828A1 (es)
SG (1) SG11201602133RA (es)
TN (1) TN2016000161A1 (es)
TW (1) TWI657089B (es)
UA (1) UA117504C2 (es)
UY (1) UY35809A (es)
WO (1) WO2015067549A1 (es)
ZA (1) ZA201602311B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
MX2017005586A (es) * 2014-11-03 2017-06-19 Bayer Pharma AG Piperidinilpirazolopirimidinonas y utilización de las mismas.
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN110590673A (zh) * 2019-09-02 2019-12-20 南通大学 一种4-氯-7-甲基-1h-吲唑及其化学合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
KR20230142746A (ko) * 2021-02-05 2023-10-11 시노허브 파마슈티컬 씨오., 엘티디 플라스민 억제제, 이의 제조 방법 및 이의 용도
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
TW202404601A (zh) 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192559A5 (en) * 1972-07-17 1974-02-08 Ugine Kuhlmann Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs
WO2006023001A1 (en) 2004-07-30 2006-03-02 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
SI2300462T1 (sl) * 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
EP2417131A4 (en) 2009-04-07 2014-08-27 Astrazeneca Ab ISOXAZOL-3 (2H) -ONE ANALOGUE AS THERAPEUTIC
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
WO2012082947A1 (en) * 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
ES2549443T3 (es) * 2010-12-16 2015-10-28 Bayer Intellectual Property Gmbh Pirimido[1,2-b]indazoles sustituidos y su uso como moduladores de la ruta de PI3K/AKT
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors

Also Published As

Publication number Publication date
US20170239251A1 (en) 2017-08-24
ZA201602311B (en) 2017-08-30
CR20160332A (es) 2016-11-10
IL244645B (en) 2019-06-30
CN105683194A (zh) 2016-06-15
AU2014345771B2 (en) 2018-09-13
TN2016000161A1 (en) 2017-10-06
DOP2016000102A (es) 2016-06-30
AP2016009175A0 (en) 2016-04-30
KR20160079093A (ko) 2016-07-05
US9598417B2 (en) 2017-03-21
CA2929378A1 (en) 2015-05-14
CL2016001076A1 (es) 2016-12-09
PE20160934A1 (es) 2016-10-08
US10098883B2 (en) 2018-10-16
JP6431061B2 (ja) 2018-11-28
US20150126449A1 (en) 2015-05-07
UA117504C2 (uk) 2018-08-10
US20180344739A1 (en) 2018-12-06
MA39018A1 (fr) 2017-06-30
GT201600084A (es) 2017-07-12
HK1223940A1 (zh) 2017-08-11
AR098292A1 (es) 2016-05-26
EP3066100A1 (en) 2016-09-14
KR102312780B1 (ko) 2021-10-15
PH12016500828A1 (en) 2016-06-13
CA2929378C (en) 2021-12-07
JP2016535052A (ja) 2016-11-10
CN105683194B (zh) 2018-09-14
EA029373B1 (ru) 2018-03-30
UY35809A (es) 2015-05-29
TWI657089B (zh) 2019-04-21
TW201609728A (zh) 2016-03-16
WO2015067549A1 (en) 2015-05-14
MX370419B (es) 2019-12-11
IL244645A0 (en) 2016-04-21
EP3066100B1 (en) 2019-04-17
AU2014345771A1 (en) 2016-04-14
EA201690935A1 (ru) 2016-10-31
US10668071B2 (en) 2020-06-02
ES2732305T3 (es) 2019-11-21
SG11201602133RA (en) 2016-05-30
MX2016005969A (es) 2016-08-11
NZ718100A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
CU24361B1 (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinólisis
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201891553A1 (ru) Ингибиторы syk
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201691881A1 (ru) Новые соединения
GEP20217247B (en) Indole derivatives for use in medicine
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
EA201591996A1 (ru) Способы и композиции для заживления раны
MX2017005586A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas.
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
ECSP12012226A (es) Composiciones y métodos para la administración no tóxica de antiprogestinas
EA201491878A8 (ru) Замещенные ксантиновые производные